Peptide Regulatory Status Tracker: 2026 Update

Framework status as of publication. This is the 2026 edition of a maintained reference. It does not publish current statuses for named compounds, because a status is only true on a date, and this page is read long after it is written. What it publishes instead is the set of frameworks a status can sit in, what each one does and does not tell you, and the method for establishing a current answer from a primary source on the day you need it.

A peptide does not have one legal status. It has a position in each of several separate frameworks, and those positions can point in different directions at once. The same molecule can be absent from any register of approved products, contested as a dietary ingredient, requested for compounding use, and prohibited in tested sport, all at once, with each of those four answers arrived at by a different body under a different test. Anyone who gives you a single yes or no has collapsed four questions into one.

This page is published by InstaMed, which sells peptide strips and therefore has a commercial interest in how this subject is described. That is a reason to check the primary sources named by category below rather than to take any seller's framing, including this one, as the answer.

Scope and method

The page covers US federal frameworks and anti-doping status. Cosmetic and topical regulation, state pharmacy rules and non-US jurisdictions are out of scope. It does not interpret a status, forecast a change, or say whether any status is appropriate. It sets out the categories and the method, and leaves the current facts to the sources that hold them.

Nothing here depends on a particular list, edition, docket or agency action, by design. Those are the parts that change, and a page that asserts them is wrong within months of being written. Evidence quality is a separate question from regulatory position, and is handled in the evidence grading standard.

Why marketing language tells you nothing

How a compound is marketed does not indicate which framework it actually sits in. A product page can call the same molecule a supplement, a research chemical, a compounded preparation or a peptide therapy, and the choice of word reflects the seller's positioning rather than any determination by a regulator. Two sellers can describe one molecule in incompatible terms and neither description is a source for anything.

The frameworks below are also not mutually exclusive. A substance can hold a position in several at the same time, and a position in one carries no implication for the others. This is the whole practical problem: the reader is usually given a marketing category and needs a regulatory one, and there is no reliable route from the first to the second. The route runs through the source documents.

The frameworks a peptide can sit inside

Active ingredient of an approved drug product

A drug product reaches the US market through an application the regulator reviews and clears, for a specified use, with approved labelling. The clearance attaches to a product, not to a molecule in general. Within its approved use, that product is a prescription medicine, and a different product containing the same molecule is not covered by it.

Dietary ingredient, including the new-dietary-ingredient pathway

Dietary supplements are marketed under a separate federal framework from drugs. Ingredients that were not in the food supply before the statutory cut-off are new dietary ingredients, and marketing one generally requires advance notification to the regulator, which responds on the record.

Two features of this framework are routinely misread. First, a notification is not an approval: it is a submission, the response to it may raise objections, and a response can take the position that the substance does not meet the definition of a dietary ingredient at all. Second, the determination is specific to an ingredient and an intended use, so a conclusion reached for one form or route does not transfer to another.

Restricted or excluded from pharmacy compounding

Compounding is governed by its own conditions, and a substance can be restricted or excluded from compounding use, either outright or outside defined circumstances. Compounding also distinguishes between types of facility, which operate under separate conditions, so "may a pharmacy compound this" and "may an outsourcing facility compound this" are two questions.

A compounding restriction is a compounding determination. It says nothing about whether the same molecule may be sold as a supplement, and nothing about approved-drug status.

Nominated for, or under consideration as, a bulk drug substance

A substance can be put forward for permitted use in compounding. The request then moves through an evaluation process with stages, public materials and advisory meetings along the way. A nomination is a request, not a permission. Appearing in a set of nominations is frequently reported as though it were clearance, and it is the opposite: it is the record of a question being asked.

Research-use-only labelling

Research-use-only is a labelling choice made by a seller, not a status any agency confers. It signals that the material is offered for laboratory use and sits outside consumer-product obligations, which means the obligations that would otherwise apply to identity, purity and labelling accuracy do not attach. It tells a buyer nothing about what is in the vial. The practical detail is in the explainer on what the research-use-only label actually means.

Anti-doping status

Anti-doping status is independent of every framework above, and it governs a different thing: eligibility in tested sport, not legality of sale. A lawfully marketed supplement ingredient can be prohibited for a tested athlete, and a substance that is absent from a prohibited-substance list by name can still fall inside a class-based catch-all category. For how the question is put for two commonly asked-about compounds, see how anti-doping status is established for BPC-157 and TB-500.

The framework table

This table is the working part of the page. Read down the first column to find the framework your question belongs to, then read across: what a position in it actually means, what it does not tell you, and the kind of source that holds the current answer.

Framework	What it means in practice	What it does not tell you	Where the answer comes from
Active ingredient of an approved drug product	A specific product has been reviewed and cleared for a specified use with approved labelling, and within that use it is a prescription medicine	Whether the molecule may be sold as a supplement, compounded, or used by a tested athlete; and whether any other product containing it is covered	The regulator's own record of approved products and their labelling, searched by product rather than by molecule name
Dietary ingredient, including the new-dietary-ingredient pathway	The ingredient is being marketed under the supplement framework, and if it is new, advance notification to the regulator is generally required before marketing	Whether a notification exists, what the response to it said, or whether the regulator accepted that the substance is a dietary ingredient at all	The regulator's published notifications and its responses to them, read for the specific ingredient and the specific intended use
Restricted or excluded from pharmacy compounding	A compounder may not use the substance, or may use it only in defined circumstances, and the conditions differ by type of facility	Anything about supplement eligibility, approved-drug status or sport, and nothing about the same molecule in a different route or form	The regulator's published compounding materials, read for the substance and for the type of facility involved
Nominated for, or under consideration as, a bulk drug substance	Someone has asked that the substance be permitted in compounding, and the request sits at some stage of an evaluation process	The outcome. A nomination is a request, and being among the nominations is not the same as being cleared for use	The regulator's published nomination and evaluation materials, including advisory meeting documents, read for the current stage
Research-use-only labelling	The seller has labelled the material for laboratory use, placing it outside consumer-product obligations	Anything about identity, purity, content, or lawfulness for any human use; and nothing conferred by any agency, because no agency confers it	The label and the seller's own documentation. No agency register records this category, which is itself the point
Anti-doping status	Governs eligibility in tested sport for the athlete, independently of whether the substance may lawfully be sold	Whether the substance may be bought or sold, and whether absence by name means clearance, since class-based wording can cover unnamed substances	The current prohibited-substance list published by the authority governing the athlete's sport, in the version in force on the relevant date

Note what the table does not contain: peptide names. That is deliberate. A row for a named compound would be a status assertion with a shelf life, and this page is built to outlast its own publication date. Where a compound is named elsewhere on this page, it is named as an example of how the question is put, never with a status attached.

How a status changes

Four mechanisms move a status, and they operate on different timescales and with different force.

Rulemaking produces binding change. A rule is proposed, a comment period runs, and a final rule issues with an effective date. It is a slow mechanism, and it leaves a documented public trail at every stage.

Guidance is not binding, but it states the regulator's current thinking and how it intends to act, which has practical effect on what suppliers and pharmacies will do. Guidance can be draft or final, and that distinction matters when you cite it.

Enforcement posture changes what is available without changing any rule. Warning letters, seizures, injunctions and import alerts remove products from the market; a decision not to act leaves them on it. Posture can shift without any document announcing that it has.

Compounding-list revision happens as substances are nominated, evaluated and categorised. Advisory meeting materials are usually the earliest public sign that a substance is being reconsidered.

Legislative activity operates on all of these. Congress can amend the statutory definitions that determine what counts as a dietary ingredient, direct agency activity through appropriations and report language, hold oversight hearings, and act on final rules. Committee referral, markup and floor action are public and dated, which makes legislative activity checkable and also makes it the stage at which reporting often runs ahead of the record. A bill introduced is not a bill passed, and a hearing held is not a change in law.

Court decisions and state pharmacy rules also affect what is actually available. Neither is a federal framework and neither is covered here.

How to verify a status yourself

1. Name the framework before asking the question. "Is it legal?" cannot be answered until you say legal for what: to sell as a supplement, to prescribe, to compound, or to take as a tested athlete.
2. Go to the primary source for that framework, in the form set out in the table above, rather than to a summary of it.
3. Search by the right handle. Approved products are found by product, not by molecule; notifications by ingredient and intended use; compounding materials by substance and facility type; anti-doping by substance and by the class it might fall into.
4. Record what you found: the document, its version or date, and the exact wording you relied on. A status without a document and a date is a rumour.
5. Check whether something later supersedes it, including a draft guidance or a proposed rule that has not taken effect.
6. Ask the seller in writing, and ask specifically. Which framework do you say this product sits in, and what document supports that? What is the intended use on the label? Who made the material, and what identity and purity documentation comes with the batch? A seller's description of a regulatory position is a marketing statement, not a source, and an unwillingness to put the answer in writing is itself information.
7. Where the answer carries commercial or clinical consequences, put it to counsel with the documents attached.

Practitioners setting a formulary will find the operational version of this, including the documentation to request from a supplier, in the overview for providers.

Why pages like this go stale

A regulatory status belongs to a date, not to an article. Any page that prints a status is accurate for as long as it takes the underlying document to be revised, and it gives no signal when that happens. The page keeps ranking, the status keeps being quoted, and the two drift apart silently.

That is why this edition holds the framework and the method rather than the facts. The framework is durable: the categories, the questions they answer, and the sources that hold them change slowly, if at all. The facts are not durable, and they are one search away in the sources named above.

Review commitment

This page is reviewed in full once a year, and the edition year in the title is updated when it is. It is revised between annual reviews only if a framework itself changes, meaning a category is added, removed or redefined. Revisions are logged with the programme's other research updates.

The commitment here is narrow and worth stating plainly: to maintain an accurate map of the frameworks and the method for using them. It is not a commitment to publish the current status of any compound, which no page can honestly keep.

Frequently Asked Questions

Is BPC-157 legal?

As asked, the question has no answer. It needs a framework attached, and there are at least four: is there an approved drug product containing it, is it eligible as a dietary ingredient for the intended use, may it be used in compounding by the type of facility in question, and is it prohibited for a tested athlete. Those four are decided by different bodies under different tests, and the answers can point in different directions. Take each one to the source named for that framework in the table above.

What does it mean when a peptide is described as a nominated bulk drug substance?

It means someone asked that it be permitted for use in compounding, and that request entered an evaluation process. It is a record of a question, not an outcome. Whether the answer has been reached, and what it is, has to be read from the current evaluation materials for that substance.

Does a new dietary ingredient notification mean the ingredient was approved?

No. A notification is a submission the regulator responds to on the record. The response may raise objections, and one available objection is that the substance does not meet the definition of a dietary ingredient at all. A filed notification is not an approval, an endorsement or a finding of safety.

If a peptide is approved as a drug in another country, can it be sold here?

A foreign approval does not create a US regulatory position. Each framework covered here is domestic, and a non-US registration is background only. The US position has to be established from US sources, for the specific product and the specific intended use.

Why do different sources give different answers for the same peptide?

Usually because they are answering different questions, and sometimes because one of them is out of date. Approved-drug status, dietary-ingredient eligibility, compounding availability and anti-doping status are four separate determinations, and a source that answers one is not wrong for failing to answer another. Check which question each source actually addressed, and on what date.

How would I know if a status changed?

Through the primary sources, checked directly: the official record of proposed and final rules for binding change, the regulator's compounding and notification records for determinations and list movement, its enforcement records for posture, the official congressional record for legislation, and the current prohibited-substance list for anti-doping. Second-hand reporting on this subject lags, and frequently misstates which framework moved.

Why does this page not just list the statuses?

Because a listed status is accurate on its publication date and unverifiable afterwards, and a reader cannot tell from the page which of those they are looking at. A framework plus a method stays correct and puts the current answer within reach. Where this page could not stand behind a current fact, it teaches the reader to obtain it instead of guessing.

Is this page legal advice?

No. It is a description of regulatory frameworks and a method for checking a position within them. A decision with commercial or clinical consequences should go to counsel with the underlying documents attached.

Questions about which framework a specific product or document sits in? Definitions and background sit in the peptide education hub, and the InstaMed contact page reaches the team. For a decision with commercial or clinical consequences, take it to your own counsel.